- Home
- CSTL vs NRDS Comparison
CSTL vs NRDS Comparison
Compare CSTL & NRDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | NRDS |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 640.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CSTL | NRDS |
|---|---|---|
| Price | $33.05 | $10.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $45.22 | $11.50 |
| AVG Volume (30 Days) | 319.5K | ★ 631.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.42 |
| EPS | N/A | ★ 0.37 |
| Revenue | $344,229,000.00 | ★ $836,600,000.00 |
| Revenue This Year | $8.49 | $9.10 |
| Revenue Next Year | $10.44 | $6.02 |
| P/E Ratio | ★ N/A | $30.09 |
| Revenue Growth | 3.66 | ★ 21.67 |
| 52 Week Low | $17.72 | $7.33 |
| 52 Week High | $44.28 | $16.24 |
Technical Indicators
Market Signals| Indicator | CSTL | NRDS |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 70.54 |
| Support Level | $31.44 | $9.45 |
| Resistance Level | $34.23 | $11.38 |
| Average True Range (ATR) | 1.69 | 0.37 |
| MACD | -0.13 | 0.19 |
| Stochastic Oscillator | 21.52 | 89.60 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.